Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14370633 | 1.00 | MGLL (0.49) | MGLLPOLBKDM1AMAOAMAOB | |
| SCHEMBL4879529 | 0.88 | MGLL (0.52) | MGLLPOLBKDM1AMAOAMAOB | |
| SCHEMBL14197109 | 0.88 | MGLL (0.52) | MGLLPOLBKDM1AMAOAMAOB | |
| SCHEMBL5378627 | 0.83 | MGLL (0.51) | MGLLPOLBKDM1AMAOAMAOB | |
| SCHEMBL14370631 | 0.83 | MGLL (0.51) | MGLLPOLBKDM1AMAOAMAOB | |
| SCHEMBL4310186 | 0.83 | MGLL (0.48) | MGLLPOLBKDM1AMAOAMAOB | |
| SCHEMBL4882489 | 0.82 | KDM1A (0.62) | MGLLPOLBKDM1AMAOAMAOB | |
| SCHEMBL14197156 | 0.82 | KDM1A (0.62) | MGLLPOLBKDM1AMAOAMAOB | |
| SCHEMBL5730852 | 0.81 | MGLL (0.54) | MGLLPOLBKDM1AMAOAMAOB | |
| SCHEMBL5373964 | 0.80 | NPC1 (0.49) | MGLLPOLBKDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279494-B2 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | PFIZER INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-20050192325-A1 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | RENSLO ADAM (US) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192325-A1 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | OXA1L, CYP51A1, CYP2C19 | MGLL 1507/4885POLB 979/4885KDM1A 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.